SCYNEXIS (NASDAQ:SCYX – Get Free Report) and Amarin (NASDAQ:AMRN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.
Profitability
This table compares SCYNEXIS and Amarin’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SCYNEXIS | -41.79% | -44.15% | -32.61% |
| Amarin | -14.56% | -0.20% | -0.14% |
Institutional and Insider Ownership
54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by company insiders. Comparatively, 4.2% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SCYNEXIS | $20.60 million | 2.12 | -$8.61 million | ($2.09) | -2.10 |
| Amarin | $186.23 million | 1.50 | -$38.80 million | ($0.99) | -13.33 |
SCYNEXIS has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
SCYNEXIS has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Amarin has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for SCYNEXIS and Amarin, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SCYNEXIS | 1 | 0 | 2 | 0 | 2.33 |
| Amarin | 2 | 1 | 0 | 0 | 1.33 |
SCYNEXIS presently has a consensus price target of $33.00, suggesting a potential upside of 651.71%. Amarin has a consensus price target of $13.00, suggesting a potential downside of 1.52%. Given SCYNEXIS’s stronger consensus rating and higher probable upside, equities analysts clearly believe SCYNEXIS is more favorable than Amarin.
Summary
SCYNEXIS beats Amarin on 8 of the 14 factors compared between the two stocks.
About SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
About Amarin
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.
